Treatment of hepatocellular carcinoma: Steps forward but still a long way to go

Liat Mlynarsky, Yoram Menachem, Oren Shibolet*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Hepatocellular carcinoma (HCC) is the fifth most common malignancy and the third cause of tumor associated deaths worldwide. HCC incidence rates are increasing in many parts of the world including developing and developed countries. Potentially curative treatments for HCC are resection and liver transplantation, but these are only suitable for patients with small tumors, meeting strict pre-defined criteria, or well-compensated liver disease. Early diagnosis of HCC can be achieved by surveillance of at-risk populations. For patients with non-resectable disease treatments modalities include loco-ablative and systemic therapies. In this review we focus on treatment options in HCC and their allocation. Although significant research is in progress, to this date, the results are unsatisfactory with limited long-term survival. In the fight against this deadly disease, there is still a long way to go.

Original languageEnglish
Pages (from-to)566-574
Number of pages9
JournalWorld Journal of Hepatology
Issue number3
StatePublished - 2015


  • Hepatocellular carcinoma
  • Liver resection
  • Liver transplantation
  • Loco-ablative therapies
  • Sorafenib


Dive into the research topics of 'Treatment of hepatocellular carcinoma: Steps forward but still a long way to go'. Together they form a unique fingerprint.

Cite this